Loading…
Chinese medical-equipment maker producing hospital sterilization, disinfection and clinical laboratory instruments.
Chinese medical-equipment maker producing hospital sterilization, disinfection and clinical laboratory instruments.
Sells sterilisers and lab instruments to hospitals mainly through public tenders, so orders follow hospital budgets and equipment-upgrade programmes. Once equipment is installed, spare parts and service bring repeat income, and drug makers buy its packaging and sterilisation lines.
In one line: A Chinese STERIS Corporation (sterilization equipment).
Moat: narrow (installed base, regulatory licence). Long hospital installed base and medical-device registration approvals favor an incumbent.
Headquarters: Zibo, Shandong, China · Employees: 7,982
Size Shinva Medical Instrument (600587.SS) is a China Health Care company (Medical Distributors) with a market value of $1.16B, the 2031st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.78 on 6 Nov 2026.
Performance Over six months the shares fell 7.0%, against -1.7% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +4.6%); the operating margin is 5.2% (peer median 1.8%).
Valuation It trades at 14.2× forward earnings against a peer median of 17.4× (4th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.6 points above its cost of capital (6.2% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.1B | CN¥9.70B | CN¥9.95B | CN¥9.93B | CN¥9.24B |
| Revenue growth | — | -3% | 0% | +7% | — |
| Gross profit | CN¥2.65B | CN¥2.33B | CN¥2.47B | CN¥2.50B | CN¥2.35B |
| EBITDA | n/a | CN¥807M | CN¥950M | CN¥917M | CN¥812M |
| Net income | CN¥453M | CN¥526M | CN¥692M | CN¥654M | CN¥500M |
| Free cash flow | CN¥647M | CN¥408M | CN¥88.5M | CN¥511M | CN¥146M |
| Capital expenditure | CN¥150M | CN¥382M | CN¥421M | CN¥536M | CN¥248M |
| Total debt | CN¥1.49B | CN¥1.56B | CN¥1.59B | CN¥1.54B | CN¥1.90B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shinva Medical Instrument 600587.SS | $1.16B | -7% | +6% | 5% | 14.2× | -5.9% |
| Steris STE | $24.6B | +22% | +8% | 20% | 21.4× | 13.7% |
| Getinge GETI-B.ST | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600587.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.6% | +1.9% | 6th lowest of 21 |
| 6-month return | -7.0% | -1.7% | 9th lowest of 21 |
| Distance from 52-week high | -26.0% | -18.4% | 7th lowest of 21 |
| Revenue growth (TTM) | +5.8% | +4.6% | 10th highest of 21 |
| Operating margin | 5.2% | 1.8% | 4th highest of 21 |
| Forward P/E | 14.2× | 17.4× | 4th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -5.9% | -1.1% | 7th least demanding of 17 |
| Growth delivered (Del g) | +1.2% | +6.1% | 3rd lowest of 17 |
| Hurdle (Req g minus delivered) | -7.1 pp | -7.7 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | +1.6 pp | +0.6 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 14.2× | -5.9% | +1.2% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | n/a | -1.3% | +17.9% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 18.2× | -1.0% | +6.3% |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | n/a | n/a | n/a |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | n/a | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 21.3× | -1.3% | +3.9% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 13.8× | -14.7% | +7.6% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 9.9× | -9.5% | +6.0% |
| Shanghai Haohai Biological Technology 688366.SS | China | $946M | -24% | -9% | -2% | 17.4× | 18.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 46.5× | 21.8% | +29.9% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 21.6× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | n/a | n/a | n/a |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 15.3× | 5.0% | +8.1% |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | n/a | 0.3% | +1.0% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 15.0× | -11.9% | +3.2% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | n/a | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 11.9× | -7.1% | +3.8% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | n/a | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | n/a | n/a | n/a |
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | n/a | 24.2% | +9.6% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 17.4× | -9.1% | +3.5% |